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Summary A bladder carcinoma cell line (J82) was selected for resistance to the new vinca alkaloid navelbine.
The resistance factor of the resistant subline (J82-NVB) to navelbine was 17. P-glycoprotein was not detected
in the membrane of J82-NVB cells. The lack of cross-resistance to multidrug-resistant (MDR) drugs such as
doxorubicin, epipodophyllotoxins and colchicine, the absence of increase in navelbine efflux and the fact that a
reduced accumulation of the drug cannot account for the resistance level confirmed that the phenotype of
resistance of J82-NVB cells is not a classical MDR phenotype. Moreover, verapamil did not reverse the
resistance of J82-NVB cells. The cells were cross-resistant to vinca alkaloids and taxoids which share the same
target protein: tubulin. Analysis of microtubules using immunofluorescence showed that disassembly of the
microtubular network occurred for the same concentration of navelbine in sensitive and resistant cells.
However, after treatment with a concentration of navelbine inducing depolymerisation in both sensitive and
resistant cells, reassembly of the microtubular network was observed only in resistant cells. This study suggests
that the mechanism of resistance of J82-NVB cells involves recovery from the inhibition of microtubule
dynamics induced by drug treatment.
The vinca alkaloids are a group of antimitotic drugs widely
used in cancer chemotherapy. Their antineoplastic activity is
related to their ability to alter microtubule dynamics (Binet et
al., 1989; Jordan et al., 1991) causing the arrest of the cells at
metaphase. However, the therapeutic efficacy of vinca alka-
loids, as well as that of other anti-tumour drugs, may be
reduced by the emergence of tumour cell resistance. One of
the major mechanisms of resistance to vinca alkaloids, called
multidrug resistance (MDR), is manifested by cross-
resistance to several structurally and functionally unrelated
compounds such as vinca alkaloids, anthracyclines,
epipodophyllotoxins, taxol, colchicine, actinomycin D and
some other drugs (Beck, 1987; Pastan & Gottesman, 1987;
Endicott & Ling, 1989). Classic MDR is characterised by the
overexpression of a membrane glycoprotein (P-glycoprotein)
which functions as a drug transporter, leading to a decreased
cellular accumulation of cytostatics (Kartner et al., 1983).
Several rnembrane transporters different from P-glycoprotein
have also been described (McClean & Hill, 1992). Other
types of resistance to vinca alkaloids have been reported,
involving decreased uptake of the drug (Haber et al., 1989)
or alterations of the target protein: tubulin (Houghton et al.,
1985; Tsuruo et al., 1986a; Pain et al., 1988; Cabral &
Barlow, 1989; Ohta et al., 1993).
In order to study the mechanisms of resistance to the new
vinca alkaloid navelbine (NVB) (Potier, 1989), two resistant
sublines (J82-NVB and K562-NVB), respectively derived
from the bladder carcinoma J82 cell line and the leukaemia
K562 cell line, were selected by exposure to navelbine.
Although the K562-NVB subline appeared to be a classic
MDR cell line, the resistance of J82-NVB cells was, on the
contrary, non P-glycoprotein mediated. The present paper
describes the characteristics of this resistance phenotype.
Materials and methods
Chemicals
Stock solutions of doxorubicin (ADM), tetrahydrophyranyl-
doxorubicin (THP-doxorubicin), aclacinomycin, methotrex-
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ate, vincristine (Bellon, Neuilly-sur-Seine, France), verapamil
(VER) (Biosedra, Malakoff, France), vinblastine (Lilly, Saint-
Cloud, France), and navelbine (Pierre Fabre Medicament,
Boulogne, France) were prepared at 1 mM in phosphate-
buffered saline (PBS). Stock solutions of etoposide,
teniposide (Sandoz, Rueil-Malmaison, France), taxol and
taxotere (Rh6ne Poulenc, Antony, France) were prepared at
10mM in dimethyl-sulphoxide (DMSO). Cycloheximide and
3,5-diaminobenzoic acid (DABA) were from Sigma Chimie
(St Quentin Fallavier, France). Solvents used for high-
performance liquid chromatography (HPLC) were HPLC
grade. All other chemicals were analytical grade.
Cells
The human bladder carcinoma cell line J82 (O'Toole et al.,
1978) was supplied by Pierre Fabre laboratories. The resis-
tant subline J82-NVB was obtained by continuous exposure
to increasing NVB concentrations from 1 to 10 nM and then
maintained at 10 nM (Pauwels & Kiss, 1991). The resistance
of J82-NVB cells was stable, since it was not decreased after
3 months of culture in the absence of drug. K562 is a human
leukaemia cell line established from a patient with chronic
myelogenous leukaemia in blast transformation (Lozzio &
Lozzio, 1975). Three resistant sublines (K562-NVB 50, 100,
200) were obtained by continuous exposure to increasing
NVB concentrations from 50 to 200 nM over a period of 12
months. The sublines obtained at each step were then main-
tained at 50, 100 and 200 nM NVB respectively. All cell lines
were grown in RPMI-1640 culture medium (Gibco, Cergy
Pontoise, France) supplemented with 10% fetal calf serum
(Institut Jacques Boy, Reims, France) in a moist air/carbon
dioxide incubator at 37C. J82 and J82-NVB cells were main-
tained as monolayers and K562 and K562-NVB cells were
suspended in the culture medium in 80 cm2 Nunc culture
flasks (Poly Labo, Strasbourg, France). For the trypsination
of J82 cells, a trypsin/EDTA solution 0.05/0.02% (w/v) in
Ca2'- and Mg2+-free PBS was used.
For drug uptake and efflux, cells in exponential growth
phase were plated and maintained in drug-free medium for 2
days and then incubated at a density of 4 x I05 cells ml-' in
RPMI medium containing the appropriate drug concentra-
tion and for the appropriate time in 80cm2 (200-250 cells
mm-2) or 175 cm2 (2,000-2,200 cells mm-2) culture flasks.
Cell densities and viability were determined by phase-contrast
microscopy with 0.1% trypan blue.
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General cell characteristics
Population doubling times were determined from daily cell
counts of triplicate cell samples incubated for 5 days in Nunc
24-well plates (Poly Labo). Cell counts were performed by
microscopy, and doubling times were determined during the
exponential growth phase. Cell diameters were measured on
trypsinised cells by microscopy, using a micrometer. Cell
protein contents were determined by the method of Lowry et
al. (1951). DNA contents were determined by fluorescence
measurement after reaction with DABA (Fiszer-Szafarz et
al., 1981).
Cell cycle analysis
DNA content was assessed using propidium iodide staining
of naked nuclei according to Vindelov et al. (1983), and
analysed with a flow cytometer (Cytofluorograf 50H, Ortho
Instruments, Westwood MA, USA) connected to a MCA-
3000 computer (Bruker, Wissembourg, France).
Growth inhibition assay
K562, K562-NVB, J82 and J82-NVB cell lines in exponential
growth phase were incubated in triplicate at 4 x I05cells
ml' for 1 h at the appropriate drug concentration in 24-well
plates (Poly Labo) under the same conditions as described
for drug uptake. The treated cells were then washed twice
with PBS at 4°C. K562 and K562-NVB cells were resus-
pended for 72 h in drug-free culture medium. J82 and J82-
NVB treated cells were kept in dishes in drug-free medium
for 72 h. For exposures in the presence of verapamil, cells
were coincubated for 1 h with 5l4M verapamil and navelbine,
washed in PBS and incubated for 72 h in medium containing
5 LM verapamil but without navelbine. Cell numbers were
then determined using phase-contrast microscopy. The
percentage of growth inhibition compared with untreated
controls was plotted against the drug concentration. IC50,
defined as the concentration of drug that reduced cell growth
by 50%, was interpolated from the curves. Resistance factors
were determined by dividing the IC50 ofresistant cells by that
of sensitive cells.
Determination ofthe intracellular concentration ofnavelbine
by high-performance liquid chromatography
Accumulation and efflux of navelbine in the tumour cells
were determined as described previously (Debal et al., 1992).
Briefly, samples of 2 x 106 cells were incubated in 5 ml of
RPMI-1640 medium containing navelbine at the appropriate
concentration. The cell suspensions (J82 and J82-NVB cells
were scraped after incubation) were centrifuged for 10 min at
200g. The pellets were washed twice with PBS. A 20yIl
aliquot of a 10-5 M vinblastine solution (internal standard)
was added to each sample. Extraction was performed by
addition of 200 tlI ethanol (pH 5.5) to each sample. Tubes
were shaken, centrifuged and 25 ll of each supernatant was
directly injected into the chromatograph.
The chromatographic system consisted of a Shimadzu
LC7A solvent-delivery module (Touzart et Matignon, Vitry
sur Seine, France), a U6K injector (Waters, St-Quentin-
Yvelines, France) and a Shimadzu RF 530 fluorescence
detector (Touzart et Matignon) set at an excitation
wavelength of 280 nm and an emission wavelength of
360 nm. Chromatograms were recorded and integrated on a
computer with a specially developed software. Separations
were performed using two columns in series: a Novapak C18
(300 x 3.9 mm i.d.) and a Novapak C,8 (150 x 3.9 mm i.d.)
(Waters). The mobile phase consisted of 60% acetonitrile and
40% phosphate buffer 25 mM (pH 2.7) containing 0.1g -'
sodium dodecyl sulphate. Navelbine amounts were deter-
mined per 106 cells.
Intranuclear measurements ofanthracyclines by laser
microspectrofluorimetry
Fluorescence emission spectra from a microvolume of a liv-
ing cell treated with THP-doxorubicin were recorded with a
confocal microspectrofluorometer (modified Raman spect-
rometer OMARS 89, Dilor, Lille, France) as already de-
scribed (Gigli et al., 1988, 1989).
Flow cytometric analysis ofP-glycoprotein expression
Direct immunofluorescence staining of P-glycoprotein was
performed using the monoclonal anti P-glycoprotein C219
antibody coupled to fluorescein (FITC). Immunostaining was
performed as described elsewhere (Cuvier et al., 1992).
Flow cytometric analyses were performed on a FACScan
flow cytometer (Becton-Dickinson, Mountain View, CA,
USA). The excitation source was an argon ion laser emitting
at 488 nm. The green fluorescence, related to P-glycoprotein
expression, was measured on a logarithmic scale.
Immunocytochemical staining ofP-glycoprotein
The cells were washed in PBS (J82 and J82-NVB cells were
harvested with trypsin), applied to microscopic slides and air
dried. They were then fixed with acetone at 4°C for 3 min,
washed in tris-buffered saline (TBS, pH 7.6), and incubated
successively with anti P-glycoprotein C219 antibody
(10tgml-' in PBS/BSA) (P-glycocheck C219, Centocor) and
unlabelled anti-mouse Ig (diluted at 1:25 in PBS/BSA). Slides
were detected with alkaline phosphatase-mouse anti-alkaline
phosphatase monoclonal antibody complexes (APAAP com-
plexes) (diluted at 1:50 in PBS/BSA) using a substrate (naph-
thol As-MX phosphate, levamisole, fast red TR salt) red
stained by alkaline phosphatase activity (Cordell et al., 1984).
After counterstaining with haematoxylin, slides were
mounted in glycerol and examined by phase-contrast micro-
scopy. The K562 myelogenous leukaemia cell line and the
doxorubicin-resistant K562-ADM subline (Tsuruo et al.,
1986b) were used as negative and positive control respec-
tively.
RNA preparation and hybridisation
Total cellular RNA from exponentially grown J82 or J82-NVB
cells were prepared by the isothiocyanate/caesium chloride
density gradient fractionation method (Sambrook et al., 1989).
The final RNA preparations were precipitated in ethanol and
adjusted to a concentration of 1 mgml-' in diethyl pyrocar-
bamate (DEPC)-treated water, then aliquoted and stored at
- 80°C. For the Northern blot analysis, 10 tg of each RNA
sample was electrophoresed on 1% agarose gels containing
formaldehyde, transferred to Hybond N+ membranes, and
stained by ethidium bromide. The probes used were the human
a-tubulin cDNA clone bal, in pUC (Cowan et al., 1983) and
the human P-tubulin cDNA clone DPl, in pUC (Hall et al.,
1983), provided by Dr N.J. Cowan (NYU Medical Center,
New York, NY, USA). The probes were nick-translated by E.
coli DNA polymerase with [a32P]dCTP (>3,000 Ci mmol- 1) as
previously described (Sambrook et al., 1989). Prehybridisation
and hybridisation were done at 42°C in 10 ml of 50% forma-
mide, 10 x Denhardt's solution, 100jigml-' salmon sperm
DNA, 1% SDS, 5 x standard saline citrate (SSC) and 25 mM
sodium phosphate pH 6.8. The heat-denatured probe was
added after 3 h of prehybridisation, and the hybridisation
reaction was left to run for 16 h. Membranes were successively
hybridised with the a-tubulin and the P-tubulin probes. Mem-
branes were washed as follows: once at room temperature in
2 x SSC, twice at 65°C in 0.5 x SSC, 0.1% SDS and twice at
room temperature in 0.2 x SSC, 0.1% SDS. The blots were
autoradiographed for 1 day on Hyperfilms MP (Amersham).1120 V. DEBAL et al.
Relative polymerised tubulin content determination
Tubulin determination was performed using an enzyme-
linked immunoassay. Cells were plated at 9,000 per well (in
0.2 ml of medium) in 96 well plates, cultured for 2 days and
then lysed and fixed as described (De Ines et al., 1994). Cells
were successively incubated with a mouse anti-a-tubulin
antibody, an anti-mouse biotinylated IgG antibody, avidin
and biotinylated horseradish peroxidase. Plates were then
developed with peroxidase substrate kit (ABTS Vector). The
absence of background was verified by omitting the first
antibody.
Immunofluorescence study ofmicrotubules
J82 and J82-NVB cells were plated on Nunc quadruple well
chamber slides in 1 ml of RPMI-1640 medium at 37°C for 2
days. Cells at 4 x I05 cells ml-' were then treated with navel-
bine (0, 50, 200, 1000, 2,000 nM) for 1 h at 37°C. Slides were
washed with ice-cold PBS and cells were fixed in 3.7% for-
maldehyde in PBS at room temperature. Cells were then
permeabilised successively in methanol and acetone at
-20°C. Slides were washed twice with PBS and incubated
with a mouse anti-x-tubulin monoclonal antibody (Sigma
Chimie, France) for 1 h at 37°C. After a 15 min wash in PBS,
the cells were stained with a fluorescein-conjugated goat anti-
mouse antibody (diluted 1:20 in PBS/BSA/sodium azide)
(Sanbio-Monosan, obtained from Tebu, Le Perray en
Yvelines, France) for 45 min at 37°C and washed again in
PBS. The slides were mounted with an anti-fading solution
and analysed with a laser scanning confocal fluorescence
microscope (MRC 600, Bio-Rad).
Results
General cell characteristics
Table I lists the general characteristics of J82 and J82-NVB
cells. The doubling times at non-confluence were similar for
J82 (18 ± 5 h) and J82-NVB (19 ± 4 h) cells. The cell
diameters and protein contents were not significantly
Table I General characteristics of J82 and K82-NVB cells
J82 J82-NVB
Doubling time (h) 18 ± 5 19 ± 4
Cell diameter (jgm) 21 ± 4 20 ± 3
Protein content 499 ± 51 457 ± 46
(Ag 10-6cells)
DNA content 27 ± 3 20 ± 3
(jig 10-6 cells)
Cell cycle distribution
GO-GI 49% 48%
S 35% 36%
G2 + M 16% 16%
different between the two cell lines. On the contrary, DNA
content was significantly higher in J82 than in J82-NVB cells
(P<0.01). Cell cycle analysis showed no difference between
J82 and J82-NVB cell cycle distribution.
Growth inhibition
The relative resistances of K562-NVB (50, 100, 200) cells to
navelbine were 35, 120 and 530 respectively.
Table II shows ICso and resistance factors obained from
J82 and J82-NVB cells (230 ± 28 cells mm-2) incubated with
different drugs as described in Materials and methods. J82-
NVB cells are cross-resistant to the three vinca alkaloids
tested, cross-resistant to taxol and taxotere, but sensitive to
all the other drugs tested (anthracyclines, epipodophyllotox-
ins and colchicine) except for a slight resistance to acla-
cinomycin. A collateral sensitivity to methotrexate was also
observed. The presence of 5 ,IM verapamil (a non-toxic con-
centration) did not reverse the resistance to navelbine. How-
ever, the IC50 values of navelbine were decreased by
verapamil for both J82 and J82-NVB cells.
Intracellular accumulation andefflux
Navelbine and THP-doxorubicin accumulation were deter-
mined in K562 cells and in the three K562-NVB sublines.
Intracellular concentrations of navelbine and THP-
doxorubicin were lower in the resistant cells than in the
sensitive cells and decreased as the resistance factors in-
creased (data not shown).
In order to determine the accumulation of navelbine in the
sensitive and resistant J82 cells as a function of incubation
time, J82 and J82-NVB cells (239 ± 42 cells mm-2) were
incubated for 0.5, 1, 2 and 3 h in RPMI-1640 medium con-
taining 2 JAM navelbine. J82-NVB cells accumulate slightly
less navelbine than J82 cells (1.7-fold less after 1 h incubation
with 2,M navelbine) (Figure 1). Drug efflux cannot account
for this difference since when 1 h-treated cells were incubated
in drug-free medium for 0.5, 1 and 3 h, efflux rates were
similar in resistant and sensitive cells (Figure 2). Verapamil
5 AM decreased the efflux rate, but intracellular concentra-
tions of navelbine remained similar in J82 and J82-NVB cells.
This decrease in efflux rate could explain the increased
growth-inhibitory effect of navelbine in the presence of
verapamil. No additional HPLC peaks indicative of meta-
bolites were observed in the chromatograms.
Accumulation of navelbine in J82 and J82-NVB cells was
also determined as a function ofextracellular drug concentra-
tion. J82 and J82-NVB cells (231 ± 32 cells mm-2) were
incubated for 1 h with 1, 2, 4 and 8 JIM navelbine. The
intracellular concentrations of navelbine were found to be
directly proportional to the extracellular concentrations
(Figure 3). Comparing accumulation and cytotoxicity of the
drug, it appears that for the same intracellular concentration,
navelbine induced more growth inhibition in J82 than in
J82-NVB cells. For example, a 281 pmol 106 cells intracel-
lular concentration of navelbine corresponds to an extracel-
Table II Cross-resistance pattern of J82-NVB cells
IC50 (nM)a Resistance
Drug J82 J82-NVB factor
Navelbine 202 ± 29 3,443 ± 614 17b
Navelbine+5laM VER 81±21 1,327 255 16b
Vinblastine 113 ± 22 1,842 ± 324 16b
Vincristine 219 ±40 4,953 834 23b
Taxol 652 86 7,867 1,313 12b
Taxotere 100 30 1,020± 190 1Ob
Colchicine 415 85 692 148 1.7
Doxorubicin 266± 55 400 85 1.5
Aclacinomycin 50 11 136± 21 2.7b
Etoposide 4,661 ± 892 6,317 ± 1,208 1.4
Teniposide 667 117 883 197 1.3
Methotrexate 8,571 ± 1,569 2,155 ± 457 0.25b
aMean±s.d. of triplicate determinations. bp <0.0I (Student's t-test).NAVELBINE-RESISTANT CARCINOMA CELL LINE 1121
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Figure I Accumulation of navelbine in J82 and J82-NVB cells as
a function of incubation time. J82 (0) and J82-NVB (-) cells
(239 ± 42 cells mm-2) were incubated for 0.5, 1, 2 and 3 h with
21iM navelbine. After each incubation period, intracellular con-
centrations of navelbine were determined using HPLC. Points,
mean of triplicate determination; bars, s.d.
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Figure 2 Efflux of navelbine from J82 and J82-NVB cells in the
presence or absence of verapamil. J82 (0, 0) and J82-NVB (U,
*) cells were incubated for I h with 2 JIM navelbine, washed and
incubated for an additional 0.5, 1 or 3 h in medium without
navelbine in the presence (0, 0) or absence (0, *) of 5 iM
verapamil. Intracellular concentrations of navelbine were deter-
mined using HPLC. Points, mean of triplicate determination;
bars, s.d.
lular concentration of 1,752 nM for J82-NVB cells and
1,000 nM for J82 cells. These concentrations induced a
growth inhibition of 19% in J82-NVB cells and of 76% in
J82 cells (per cent of control). So the slightly decreased
accumulation of navelbine in J82-NVB cells cannot account
for the resistance factor.
Effect ofcell confluence on drug accumulation and cytotoxicity
J82 and J82-NVB cells in monolayer culture have somewhat
different morphologies. J82 cells are pleiomorphic, exhibiting
either an epithelial or a fibroblastic morphology. J82-NVB
cells appear more homogeneous with almost only epithelial
morphologies. These morphological differences are accom-
panied by differences in confluence between sensitive and
resistant cells. In non-confluent monolayers (200-250 cells
mm 2), J82 cells appeared more dispersed than J82-NVB
cells. In order to study the effect of this difference on navel-
bine accumulation, J82 and J82-NVB cells were incubated
with navelbine for 1 h under the same conditions as described
Navelbine concentration in the medium (PM)
Figure 3 Accumulation of navelbine in J82 and J82-NVB cells as
a function of navelbine concentration in the medium. J82 (0)
and J82-NVB (D) cells (231 ± 32 cells mm-2) were incubated for
I h with 1, 2, 4 and 8JIM navelbine. Intracellular concentrations
of navelbine were determined using HPLC. Points, mean of
triplicate determination; bars, s.d.
above except that cells were confluent (2,100 + 210 cellsmm-2).
Under these conditions, accumulation of navelbine was
similar in J82 and J82-NVB cells and lower than in non-
confluent cells (Table III). Navelbine concentration was
decreased more in J82 than in J82-NVB confluent cells com-
pared with non-confluent cells.
The effect of confluence on navelbine cytotoxicity was also
tested. Confluent (2,020 ± 190 cells mm-2) and non-confluent
(235 ± 39 cells mm-2) cells were incubated as described in the
Materials and methods section. After a 1 h incubation with
navelbine, cells were trypsinised and plated at 230 cells mm-2
(non-confluent) in drug-free medium for 72 h. Counting was
performed as described above. When cells were incubated at
confluence, the cytotoxicity of the drug was decreased com-
pared with non-confluent cells. This effect was more impor-
tant in J82 than in J82-NVB cells so that the resistance factor
was decreased from 17 to 10 (Table III). This confirms that a
decreased uptake is not responsible for J82-NVB cell resis-
tance since navelbine accumulation is similar in confluent J82
and J82-NVB cells but induced more growth inhibition in J82
cells.
P-glycoprotein expression
Flow cytometric analysis showed that P-glycoprotein was
overexpressed in the K562-NVB cell sublines and in K562-
ADM cells compared with K562 cells (Figure 4a, b, e and f).
Conversely, P-glycoprotein expression was not increased in
J82-NVB cells compared with J82 cells (Figure 4c and d).
No P-glycoprotein overexpression was detected in J82 or in
J82-NVB cells using immunocytochemistry with C219 anti-
bodies (not shown). P-glycoprotein was detected in the mem-
brane of K562-ADM cells but not in that of K562 cells, used
as positive and negative controls respectively.
Total andpolymerised tubulin amounts
a- and P-tubulin mRNA expressions were found to be similar
in J82 and J82-NVB cells by Northern blot analysis (Figure
5). The amounts of polymerised tubulin determined by
enzyme-linked immunoassay were similar in J82 and J82-
NVB cells.
Immunofluorescence study ofmicrotubules
Figure 6a and b shows the microtubular network of un-
treated J82 and J82-NVB cells. Treatment of the cells for 1 h
with navelbine at concentrations ranging from 50 to 2,000 nM
induced a progressive depolymerisation of microtubules. In
ti)1122 V. DEBAL et al.
Table III Influence of cell confluence on intracellular concentration and cytotoxicity
of navelbine
Intracellular4
Cell Cell concentration IC50 Resistance
confluence line (pmol10'6 cells) (nM) factor
Non-confluent J82 469 ± 38b 185 35b
J82-NVB 279 ± 22 3239 388 17
Confluent J82 272 ± 28C 380+ 68d
J82-NVB 254 ± 20 3915 605 10
aThe cells were incubated for 1 h in culture medium containing 2JiM navelbine.
bMean ± s.d. of triplicate determinations. cSignificantly different (P <0.01) compared
with non-confluent cells. dSignificantly different (P <0.05) compared with non-confluent
cells.
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Figure 4 Flow cytometric analysis of P-glycoprotein expression.
K562-NVB 50 (a), K562-NVB 100 (b), J82 (c), J82-NVB (d),
K562 (e), and K562-ADM (f), cells were stained using an anti-P-
glycoprotein antibody coupled to fluorescein. K562 and K562-
ADM cells were used as negative and positive control respec-
tively. Clear area, isotypic control; grey area, assay with the C219
antibody.
cells treated with 50 nM navelbine, no depolymerisation
occurred. With 200 nM navelbine, a complete depolymerisa-
tion of the microtubular network was observed in 25% of the
sensitive cells (Figure 6c) and in 29% of the resistant cells
(Figure 6d). With 1,000 nM navelbine, microtubules appeared
completely disassembled in more than 90% of the cells. With
2,000 nM navelbine, a complete depolymerisation of the mic-
rotubules was observed in both sensitive and resistant cells
(Figure 6e and f). So, the complete disassembly of the micro-
tubular network occurred at equivalent navelbine concentra-
tions in J82-NVB and in J82 cells. The reversibility of the
Total RNA
a-Tubulin
1-Tubulin
1 = J82 2 = J82-NVB
Figure 5 Northern blot analysis of oa- and P-tubulin expression
in J82 and J82-NVB cells. Total cellular RNA was extracted from
the cells, electrophoresed. transferred to Hybond N+ membranes
and hybridised with a-tubulin and P-tubulin probes.
depolymerisation mechanism was also tested. When the cells
were treated with 2,000 nM navelbine for 1 h and then
incubated for an additional 6 h in drug-free medium,
reassembly of microtubules was observed only in resistant
and not in sensitive cells (Figure 6g and h). The same result
was obtained with vinblastine. On the contrary, no rever-
sibility was observed after treatment of the cells with
2,000 nM colchicine (not shown).
Effect ofcycloheximide on cell resistance and on reassembly of
microtubules
We have tested the effect of cycloheximide, an inhibitor of
protein synthesis, on the resistance of J82-NVB cells. The
growth inhibition assay was performed as described in the
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Materials and methods section. J82 and J82-NVB cells were
incubated for 1 h in medium containing navelbine with or
without 50fgml-' cycloheximide. The cells were then
washed and incubated in drug-free medium for 72 h. Cell
numbers were then determined. The IC50 of navelbine was
not modified by the treatment with cycloheximide in sensitive
cells but was slightly decreased in resistant cells (Table IV).
The resistance factor was decreased from 17 to 11. The cells
were also treated for 1 h in medium containing 2,000 nM
navelbine and 501agml-' cycloheximide and then incubated
for 6 h in medium containing 50 S,g ml-' cycloheximide but
without navelbine. Microtubules were studied as described
above. Reassembly of microtubules was observed in resistant
cells even in the presence of cycloheximide (data not
shown).
a
e
Figure 6 Study of the microtubular network of J82 and J82-
NVB cells using immunofluorescence. J82 (a, c, e and g) and
J82-NVB (b, d, f and h) cells were incubated for 1 h in RPMI
medium, free of drug (a and b) or containing 200 nM (c and d) or
2,000 nM (e and f) navelbine. In order to study the reversibility of
microtubule depolymerisation, the cells, incubated for 1 h with
2,000 nM navelbine, were incubated for an additional 6 h in
drug-free medium (g and h). The cells were fixed and tubulin was
stained using a mouse anti-a-tubulin antibody followed by a
fluorescein-conjugated anti-mouse antibody. The slides were
viewed with a laser scanning confocal fluorescence microscope
(MRC 600, Bio-Rad). Bar = 15gm.
Discussion
In the present study, we have described the characteristics of
a bladder carcinoma cell line, J82-NVB, selected for resis-
tance to navelbine. The results show that the resistance
phenotype of this cell line is not a MDR phenotype. P-
glycoprotein was not detected in the membrane of J82-NVB
cells. Atypical resistance phenotype was confirmed by the
lack of cross-resistance to MDR drugs such as doxorubicin,
epipodophyllotoxin and colchicine, by the absence ofincrease
in navelbine efflux and by the fact that a reduced accumula-
tion of the drug could not account for the observed resis-
tance level. At equally toxic concentrations, J82-NVB cells
accumulate more navelbine than J82 cells. Moreover,
verapamil, a drug known to reverse multidrug resistance
(Tsuruo et al., 1982; Cass et al., 1989), did not decrease the
relative resistance of J82-NVB cells to navelbine compared
with sensitive cells.
Few reports have described navelbine resistance
mechanisms. We had already shown (Debal et al., 1992) that
in the K562-ADM cell line, which is a classic MDR cell line
(Tsuruo et al., 1986b) selected for resistance to doxorubicin,
navelbine accumulation was greatly decreased compared with
the sensitive K562 cells. We report here that three K562
resistant sublines selected for resistance in the presence of
navelbine are also classic MDR cell lines with increased
expression of P-glycoprotein, cross-resistance to navelbine
and doxorubicin and reduced drug accumulation. So, it
appears that the non-MDR phenotype observed in J82-NVB
cells is not due to the use of navelbine as a resistance inducer
but is rather a characteristic of this cell line or of the
procedure used for the resistance induction. It has been
reported that J82 cells selected for resistance to I ZlM navel-
bine (100-fold more than for our cells) displayed a classic
MDR phenotype (Etievant et al., 1993). Thus, it appears that
the resistance phenotype observed is linked to the concentra-
tion ofdrug used for the resistance selection. Such a relation-
ship has already been reported in other cell lines in which
non-P-glycoprotein mechanisms of resistance preceded P-
glycoprotein expression (Baas et al., 1990).
J82 cells have been described as poorly differentiated
epithelial cells with a heterogeneous population morphology
(O'Toole et al., 1978). Some morphological differences
appear between J82 and J82-NVB cells. The J82 cell popula-
tion displays both epithelial and fibroblastic morphologies
while almost all J82-NVB cells are of the epithelial type. This
is accompanied by a greater dispersion of the sensitive cells
in non-confluent monolayers. It has been reported that in
cells cultured as monolayers cell confluence could play a role
in cell resistance. A decreased drug influx in confluent cells
compared with non-confluent cells could be responsible for a
decreased drug cytotoxicity (Pelletier et al., 1990). We have
studied navelbine accumulation and cytotoxicity in confluent
and non-confluent J82 and J82-NVB cell monolayers. We
have shown that cell confluence could induce some resistance
to navelbine in J82 cells and to a lower extent in J82-NVB
cells. However, the difference of cohesion between J82 and
J82-NVB cell monolayers can only account for a small part
of the level of resistance to navelbine, and this resistance
level could only be explained by the involvement of some
other mechanism.
Apart from mechanism involving a drecreased accumula-
tion of the drug, other types of resistance to vinca alkaloids
have been described. These drugs have been reported to
affect glutathione metabolism (Beck, 1980; Whelan et al.,
Table IV Influence of cycloheximide
navelb
Drug
Navelbine
Navelbine +
cycloheximide 50 Lg ml'
on the growth-inhibitory effect of
IC50 (nM) Resistance
IC,50 (nM)
J82 J82-NVB
202± 29 3,443± 614
259± 42 2,906± 350
Resistance
factor
17
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1992), but the involvement of this mechanism in vinca
alkaloid resistance has not been proved. Intracellular redistri-
bution of the drug should also be considered since such a
mechanism has been described in several resistant cell lines
(Hindenburg, 1987; Cole, 1992). However, this mechanism
could induce resistance to several functionally unrelated
drugs while J82-NVB cell resistance is limited to vinca
alkaloids and taxoids which share a common target site:
tubulin (Gueritte-Voegelein et al., 1991; Jordan et al., 1991).
Therefore, J82-NVB cell resistance is most probably linked to
the alteration of some microtubule property. Several reports
have described various modifications of tubulin in vinca
alkaloid-resistant cell lines. A diminished amount (Tsuruo et
al., 1986a; Ohta et al., 1993) or an increased amount of
tubulin has been described in resistant cell lines. However,
the study ofa- and P-tubulin expression showed no difference
between J82 and J82-NVB cell lines. Structural alterations of
tubulin in resistant cells could lessen the affinity of tubulin
for the drug (Pain et al., 1988) or induce the hyperstabilisa-
tion of the microtubules (Cabral & Barlow, 1989). However,
cells possessing hyperstable microtubules are cross-resistant
to depolymerising drugs such as vinca alkaloids and colchi-
cine and hypersensitive to stabilising drugs such as taxol
(Keates et al., 1981; Minotti et al., 1991). This is not the case
for our J82-NVB cells, which are sensitive to colchicine and
cross-resistant to taxol and taxotere. So, it seems unlikely
that hyperpolymerisation of tubulin could be responsible for
J82-NVB cell resistance. Moreover, the amounts of
polymerised tubulin were found to be similar in J82 and
J82-NVB cells.
We have shown that the resistance of J82-NVB cells is
linked to the differentiation state of the cells (V. Debal et al.,
submitted). When the resistant cells were differentiated by
retinoic acid, their resistance was lost. This shows that the
mechanism of resistance is not due to tubulin mutation, but
rather to modifications of some mechanism regulating micro-
tubule dynamics.
Using immunofluorescence, we have studied the micro-
tubules of J82 and J82-NVB cells treated with navelbine.
After incubation with navelbine, depolymerisation of the
microtubules occurred at nearly the same drug concentration
in sensitive and in resistant cells. This shows that even in
resistant cells the drug reached its target and was not
sequestered in some subcellular compartment. Microtubule
depolymerisation in J82 cells treated for 1 h with navelbine
occurred approximately at the drug concentration which
induced a growth inhibition, while in J82-NVB cells growth
inhibition occurred at concentrations higher than those
inducing depolymerisation. So, the effect of the drug on
microtubules was nearly the same in sensitive and in resistant
cells, but resistant cells could survive after removal of the
drug whereas sensitive cells could not. Thus, recovery from
the inhibition of microtubule dynamics induced by navelbine
is probably responsible for the resistance of J82-NVB
cells.
In order to study this recovery mechanism, we have tested
the reversibility of microtuble depolymerisation in sensitive
and resistant cells. After treatment with 2,000 nM navelbine,
reassembly of the microtubular network was observed in
resistant but not in sensitive cells. The same result was
obtained with vinblastine. Moreover, no reversibility was
observed after treatment with colchicine, to which the cells
are not resistant. This confirms that the mechanism of resis-
tance of J82-NVB cells is at the level of microtubules and
involves recovery of microtubule dynamics.
Some mechanisms allowing recovery from cellular damage
induced by protein alteration have already been described.
They generally involve the synthesis of proteins of the family
of molecular chaperones (Ellis & Van der Vries, 1991).
Moreover, molecular chaperone proteins play an essential
role in the in vivo assembly of microtubules (Gupta, 1990).
Some of these proteins have been reported to induce cell
resistance to vinca alkaloids (Huot et al., 1991; Lee et al.,
1992), and these newly synthesised proteins have been found
to bind to tubulin in these resistant cells (Lee et al., 1992).
We have tested the effect of cycloheximide, an inhibitor of
protein synthesis, on the resistance ofJ82-NVB cells to navel-
bine. The presence of cycloheximide during the incubation of
J82-NVB cells with navelbine results in only a slight decrease
of resistance, and reassembly of microtubules occurs in J82-
NVB cells even in the presence of cycloheximide. Thus it
seems that protein synthesis is not essential for the recovery
to occur.
The cross-resistance observed between vinca alkaloids and
taxoids may appear rather surprising since vinca alkaloids,
like colchicine, are microtubule-depolymerising drugs, cont-
rary to taxol, which promotes tubulin polymerisation (Schiff
et al., 1979). However, it has been shown that the antipro-
liferative action of vinca alkaloids at low concentration
results from stabilisation of microtubule dynamic instability
rather than from depolymerisation of microtubules (Jordan
et al., 1991; Toso et al., 1993). Recently, it has been shown
that taxol, at low concentration, shares a common antipro-
liferative mechanism with vinca alkaloids (Jordan et al.,
1993). In our cells, low concentrations of the drug remained
after removal of the drug from the medium. Under these
conditions, the mechanism of action of vinca alkaloids and
taxol analogues are similar. Moreover, cross-resistance
between vinca alkaloids and taxol has already been observed
in another non-MDR cell line resistant to microtubule
poisons (Ohta et al., 1993). Other authors have studied the
reversibility of microtubules bundling induced by taxol in
different leukaemia cell lines (Rowinsky et al., 1988). They
concluded that in cells that were relatively resistant to taxol
microtubule bundling was reversible, unlike in relatively sen-
sitive cells, in which microtubule bundles persisted.
All these results are consistent with our study, which sug-
gests that the mechanism of resistance of J82-NVB cells is
mainly recovery from the inhibition of microtubule
dynamism induced by the drug.
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